Life Edit Therapeutics
Andrew Chan, Ph.D., is an experienced scientist specializing in protein chemistry and metabolic engineering, currently holding positions as Scientist II at ElevateBio and Life Edit Therapeutics since March 2022. Prior experience includes roles as a Scientist at DMC Biotechnologies, Inc. and Postdoctoral Research Fellow at McMaster University. Andrew has a strong background in biochemical techniques and has investigated various topics, including the mechanism of action of the antibiotic holomycin and the magnetic navigation of loggerhead sea turtle hatchlings. Educational achievements include a Ph.D. in Biological Chemistry from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from the same institution.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.